Drugs / ACI-24
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial · 1 met primary | ||||||
| Phase 2 | NCT04373616 | Oct 2021 → Apr 2024 | Down syndrome | AC Immune SA | Withdrawn | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT02738450 Comparator | Mar 2016 → Jun 2020 | Down syndrome | AC Immune SA | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 9
| Date | Issuer | Release |
|---|---|---|
| 2026-06-30 | AC Immune SA | Results AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer’s Disease acimmune.com ↗
In the trial to date, ACI-24 has been generally safe and well tolerated, with no evidence of amyloid-related imaging abnormalities-edema (ARIA-E). |
| 2023-01-26 | AC Immune SA | Results AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial acimmune.com ↗
ACI-24.060 was generally well tolerated with no safety concerns observed |
| 2022-05-09 | AC Immune SA | Results AC Immune’s Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology acimmune.com ↗
today announced the publication in JAMA Neurology 1 of data showing that AC Immune's ACI-24 anti-Abeta vaccine was found to be safe and elicited immune response in a Phase 1b clinical trial in adults with DS. |
| 2022-02-04 | AC Immune SA | Results AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease acimmune.com ↗
Data published today in the Brain Communications paper show the optimized ACI-24 formulation induced a broad polyclonal anti-Abeta response, including high titers of antibodies targeting pyroGlu-Abeta variants, and was well tolerated in non-human primates and mice. |
| 2021-07-29 | AC Immune SA | Results AC Immune Presents Full Phase 1b Results on Anti-Abeta Vaccine and Discusses its First-in-Class Diagnostic for Parkinson’s Disease at AAIC 2021 acimmune.com ↗
The Phase 1b study results showed that ACI-24 was safe and well tolerated in adults with DS. |
| 2021-06-02 | AC Immune SA | Results AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta acimmune.com ↗
Phase 2 interim analysis of ACI-24 confirms good safety and tolerability profile in people with mild Alzheimer’s disease |
| 2021-03-16 | AC Immune SA | Results AC Immune Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine acimmune.com ↗ |
| 2019-08-14 | AC Immune SA | Results AC Immune Reports Q2 2019 Financial Results, Business and Clinical Update acimmune.com ↗
Initial interim data from an ongoing Phase 1b trial of AC Immune’s ACI-24 anti-Abeta vaccine, to treat AD like symptoms in subjects with Down syndrome (DS), demonstrated strong safety and preliminary immunogenicity results |
| 2019-07-11 | AC Immune SA | Results AC Immune Hosts KOL Event and Reports Initial Interim Clinical Data for ACI-24 Vaccine to Treat Alzheimer’s Disease-like Symptoms in Subjects with Down Syndrome acimmune.com ↗
These initial interim Phase 1b data support the continued study of ACI-24 in this trial to treat AD-like symptoms in DS as well as in our ongoing Phase 2 trial in subjects with mild AD. |
All press releases naming this drug 13 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ACI-24 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04373616 ↗ |
| Modality | Vaccine | “The liposome-based antiamyloid ACI-24 vaccine is intended to treat neurological disorders caused by misfolded Aβ pathological protein.” PMID 35532913 ↗ Jun 2022 |